JOP20170038B1 - مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه - Google Patents
مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منهInfo
- Publication number
- JOP20170038B1 JOP20170038B1 JOP/2017/0038A JOP20170038A JOP20170038B1 JO P20170038 B1 JOP20170038 B1 JO P20170038B1 JO P20170038 A JOP20170038 A JO P20170038A JO P20170038 B1 JOP20170038 B1 JO P20170038B1
- Authority
- JO
- Jordan
- Prior art keywords
- prophylaxis
- treatment
- hiv
- compounds
- hiv infection
- Prior art date
Links
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
العكسي لـ HIV، وعلاج عدوى HIV، والوقاية من عدوى HIV، وعلاج، ووقاية و/أو تأخير بدء أو تقدم AIDS أو ARC عن طريق إعطاء مركب بالصيغة البنائية I
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294576P | 2016-02-12 | 2016-02-12 | |
| US201662297657P | 2016-02-19 | 2016-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20170038B1 true JOP20170038B1 (ar) | 2021-08-17 |
Family
ID=58057333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2017/0038A JOP20170038B1 (ar) | 2016-02-12 | 2017-02-09 | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US10537589B2 (ar) |
| EP (1) | EP3413897B1 (ar) |
| JP (4) | JP6810972B2 (ar) |
| KR (3) | KR20220126787A (ar) |
| CN (2) | CN113509480A (ar) |
| AU (3) | AU2017217656B2 (ar) |
| BR (1) | BR112018016349A2 (ar) |
| CA (1) | CA3013473C (ar) |
| CL (1) | CL2018002150A1 (ar) |
| DK (1) | DK3413897T3 (ar) |
| DO (1) | DOP2018000183A (ar) |
| EA (1) | EA201891814A1 (ar) |
| ES (1) | ES2953535T3 (ar) |
| FI (1) | FI3413897T3 (ar) |
| GE (1) | GEP20217231B (ar) |
| HK (1) | HK1257347A1 (ar) |
| HR (1) | HRP20230935T1 (ar) |
| HU (1) | HUE063532T2 (ar) |
| IL (1) | IL260874B2 (ar) |
| JO (1) | JOP20170038B1 (ar) |
| LT (1) | LT3413897T (ar) |
| MD (1) | MD3413897T2 (ar) |
| MX (3) | MX2022002925A (ar) |
| MY (1) | MY197090A (ar) |
| NI (1) | NI201800083A (ar) |
| NZ (1) | NZ745065A (ar) |
| PH (1) | PH12018501712A1 (ar) |
| PL (1) | PL3413897T3 (ar) |
| PT (1) | PT3413897T (ar) |
| RS (1) | RS64448B1 (ar) |
| SG (1) | SG11201806783WA (ar) |
| SI (1) | SI3413897T1 (ar) |
| SV (1) | SV2018005733A (ar) |
| TN (1) | TN2018000267A1 (ar) |
| TW (2) | TWI822652B (ar) |
| UA (1) | UA126375C2 (ar) |
| WO (1) | WO2017139519A1 (ar) |
| ZA (1) | ZA201805073B (ar) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| US20200138845A1 (en) * | 2017-07-18 | 2020-05-07 | Viiv Healthcare Company | Combination Drug Therapy |
| CN109893536B (zh) * | 2018-07-02 | 2021-04-27 | 河南真实生物科技有限公司 | 4’-取代核苷的晶型、制备和应用 |
| US12005072B2 (en) | 2018-07-17 | 2024-06-11 | Merck Sharp & Dohme Llc | HIV drug combination for increasing barrier against resistance |
| CN113194959A (zh) * | 2018-12-20 | 2021-07-30 | 默沙东公司 | Nrtti化合物的新型结晶形式 |
| KR20210137434A (ko) | 2019-01-25 | 2021-11-17 | 브라운 유니버시티 | 연령 관련 염증 및 장애를 치료, 예방 또는 역전시키기 위한 조성물 및 방법 |
| JP2022525013A (ja) * | 2019-03-06 | 2022-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド | Ｈｉｖ療法において有用な化合物 |
| WO2023196832A2 (en) * | 2022-04-06 | 2023-10-12 | Brii Biosciences, Inc. | Pharmaceutical composition and method for treatment of human immunodeficiency virus infections |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1655033A1 (en) * | 1995-06-07 | 2006-05-10 | Emory University | Nucleosides with anti-hepatitis B virus activity |
| BRPI0407374A (pt) | 2003-02-19 | 2006-01-10 | Univ Yale | Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| US8513205B2 (en) * | 2008-04-11 | 2013-08-20 | Yale University | Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase |
| WO2012099630A1 (en) * | 2011-01-20 | 2012-07-26 | University Of Rochester | Compositions and methods for treating or preventing a retrovirus infection |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| WO2017053216A2 (en) | 2015-09-23 | 2017-03-30 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof |
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| MX2018013662A (es) * | 2016-05-12 | 2019-03-01 | Merck Sharp & Dohme | Sistema de entrega de farmacos para la entrega de agentes antivirales. |
| US20190388336A1 (en) * | 2016-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Drug Delivery System for the Delivery of Antiviral Agents |
| US20200138845A1 (en) * | 2017-07-18 | 2020-05-07 | Viiv Healthcare Company | Combination Drug Therapy |
| PE20220707A1 (es) * | 2019-08-13 | 2022-05-04 | Merck Sharp & Dohme | Sistema de administracion de medicamentos para la administracion de agentes antiviricos |
| EP4146302A4 (en) * | 2020-05-05 | 2024-05-22 | Merck Sharp & Dohme LLC | DRUG DELIVERY SYSTEM FOR DELIVERING ANTIVIRAL AGENTS AND CONTRACEPTS |
| EP4203917A4 (en) * | 2020-08-25 | 2024-10-09 | Merck Sharp & Dohme Llc | INJECTABLE DEPOT COMPOSITIONS FOR THE ADMINISTRATION OF ANTIVIRAL AGENTS |
-
2017
- 2017-02-09 JO JOP/2017/0038A patent/JOP20170038B1/ar active
- 2017-02-10 IL IL260874A patent/IL260874B2/en unknown
- 2017-02-10 SI SI201731395T patent/SI3413897T1/sl unknown
- 2017-02-10 CA CA3013473A patent/CA3013473C/en active Active
- 2017-02-10 KR KR1020227029968A patent/KR20220126787A/ko not_active Application Discontinuation
- 2017-02-10 TW TW106104527A patent/TWI822652B/zh active
- 2017-02-10 GE GEAP201715046A patent/GEP20217231B/en unknown
- 2017-02-10 AU AU2017217656A patent/AU2017217656B2/en active Active
- 2017-02-10 HR HRP20230935TT patent/HRP20230935T1/hr unknown
- 2017-02-10 MX MX2022002925A patent/MX2022002925A/es unknown
- 2017-02-10 RS RS20230656A patent/RS64448B1/sr unknown
- 2017-02-10 TN TNP/2018/000267A patent/TN2018000267A1/en unknown
- 2017-02-10 TW TW112126073A patent/TW202417010A/zh unknown
- 2017-02-10 FI FIEP17706102.5T patent/FI3413897T3/fi active
- 2017-02-10 US US15/430,016 patent/US10537589B2/en active Active
- 2017-02-10 ES ES17706102T patent/ES2953535T3/es active Active
- 2017-02-10 MD MDE20181208T patent/MD3413897T2/ro unknown
- 2017-02-10 KR KR1020217012504A patent/KR20210049201A/ko active Application Filing
- 2017-02-10 UA UAA201809259A patent/UA126375C2/uk unknown
- 2017-02-10 NZ NZ745065A patent/NZ745065A/en unknown
- 2017-02-10 CN CN202110783129.4A patent/CN113509480A/zh active Pending
- 2017-02-10 DK DK17706102.5T patent/DK3413897T3/da active
- 2017-02-10 WO PCT/US2017/017283 patent/WO2017139519A1/en active Application Filing
- 2017-02-10 JP JP2018541685A patent/JP6810972B2/ja active Active
- 2017-02-10 CN CN201780010879.XA patent/CN108697727A/zh active Pending
- 2017-02-10 EP EP17706102.5A patent/EP3413897B1/en active Active
- 2017-02-10 PL PL17706102.5T patent/PL3413897T3/pl unknown
- 2017-02-10 BR BR112018016349A patent/BR112018016349A2/pt not_active Application Discontinuation
- 2017-02-10 MX MX2022002924A patent/MX2022002924A/es unknown
- 2017-02-10 MY MYPI2018001425A patent/MY197090A/en unknown
- 2017-02-10 MX MX2018009763A patent/MX2018009763A/es unknown
- 2017-02-10 SG SG11201806783WA patent/SG11201806783WA/en unknown
- 2017-02-10 LT LTEPPCT/US2017/017283T patent/LT3413897T/lt unknown
- 2017-02-10 KR KR1020187025948A patent/KR102317570B1/ko active IP Right Grant
- 2017-02-10 HU HUE17706102A patent/HUE063532T2/hu unknown
- 2017-02-10 EA EA201891814A patent/EA201891814A1/ru unknown
- 2017-02-10 PT PT177061025T patent/PT3413897T/pt unknown
-
2018
- 2018-07-27 ZA ZA2018/05073A patent/ZA201805073B/en unknown
- 2018-08-08 CL CL2018002150A patent/CL2018002150A1/es unknown
- 2018-08-08 NI NI201800083A patent/NI201800083A/es unknown
- 2018-08-09 SV SV2018005733A patent/SV2018005733A/es unknown
- 2018-08-10 DO DO2018000183A patent/DOP2018000183A/es unknown
- 2018-08-13 PH PH12018501712A patent/PH12018501712A1/en unknown
- 2018-12-24 HK HK18116555.3A patent/HK1257347A1/zh unknown
-
2019
- 2019-12-11 US US16/710,875 patent/US11337991B2/en active Active
-
2020
- 2020-04-30 AU AU2020202866A patent/AU2020202866B2/en active Active
- 2020-09-11 JP JP2020153037A patent/JP7021314B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015456A patent/JP2022062170A/ja active Pending
- 2022-03-10 AU AU2022201686A patent/AU2022201686B2/en active Active
- 2022-04-08 US US17/658,547 patent/US20220331350A1/en active Pending
-
2023
- 2023-10-06 JP JP2023174548A patent/JP7559175B6/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20170038B1 (ar) | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه | |
| NZ724343A (en) | 4’-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors | |
| MX2019007262A (es) | Compuestos antivirales de bencilamina fosfodiamida. | |
| SA519402405B1 (ar) | مركبات مثبط فيروس نقص المناعة البشري | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CA2998646C (en) | 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof | |
| SG11201901061QA (en) | Heterocyclic compound | |
| TN2018000048A1 (en) | Antiviral beta-amino acid ester phosphodiamide compounds | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| NZ746825A (en) | Oxysterols and methods of use thereof | |
| SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
| MX2016012915A (es) | Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih). | |
| WO2015017393A3 (en) | Piperazine derivatives as hiv protease inhibitors | |
| MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
| MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. | |
| MX2020009287A (es) | Nuevo compuesto y composicion farmaceutica que lo comprende. | |
| EA201991208A1 (ru) | Способы лечения множественного остеохондроматоза (мо) | |
| MX2021003481A (es) | Compuesto heterociclico. | |
| AR107596A1 (es) | Procedimientos para el tratamiento y la profilaxis de vih y sida | |
| EA201991932A1 (ru) | Производное азитидина |